文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

既往治疗后再行挽救性质子治疗的前列腺癌患者直肠周围间隔物植入的可行性与结局

Feasibility and Outcomes of Perirectal Spacer Implantation in Previously Treated Prostate Cancer Patients Undergoing Salvage Proton Therapy Radiation.
PubMed 文献 · Adv Radiat Oncol · 2026-02-09

该回顾性研究纳入30例活检证实局部复发且既往接受过局部治疗的前列腺腺癌患者,在纽约质子中心接受挽救性质子治疗并尝试直肠周围间隔物植入。间隔物植入成功率为93%(28/30),2例因纤维化过重中止;中位随访12.5个月,仅3例出现1级腹泻,无≥2级毒性或操作并发症。

要点

  • 既往盆腔放疗或局部治疗后行挽救性质子治疗时,直肠周围间隔物植入可行,成功率为93%。
  • 间隔物植入后中位直肠Dmax为91.55%,7例Dmax>100%,其中3例有HIFU史。
  • 中位随访12.5个月,仅3例1级腹泻,无≥2级毒性或操作并发症。

核心结论

  • 既往接受过盆腔局部治疗的前列腺癌患者行挽救性质子治疗时,直肠周围间隔物植入可行且安全,多数患者可成功放置,毒性轻微且剂量学结果良好。

研究设计与样本

  • 回顾性研究纳入30例活检证实局部复发的前列腺腺癌患者,均既往接受过HIFU、近距离治疗、外照射或近距离联合外照射,在纽约质子中心(2020-2024)接受挽救性质子治疗并尝试直肠周围间隔物(SpaceOAR或Barrigel)植入。

主要发现

  • 30例中28例(93%)成功完成间隔物植入,2例因纤维化过重中止。
  • 中位最大和最小中轴前后分离距离分别为10.8 mm和3.5 mm。
  • 中位直肠Dmax为91.55%(范围44%-102.4%),7例Dmax>100%,其中3例有HIFU史。
  • 中位随访12.5个月,胃肠道毒性仅见1级腹泻3例,无≥2级毒性或操作并发症报告。

关键数值与推荐

  • 间隔物植入成功率93%(28/30);中位最大和最小中轴前后分离距离分别为10.8 mm和3.5 mm;中位直肠Dmax为91.55%(范围44%-102.4%)。

临床怎么用

  • 对既往接受过盆腔放疗或局部治疗的前列腺癌复发患者,挽救性质子治疗前可考虑尝试直肠周围间隔物植入以降低直肠剂量,但HIFU治疗后患者操作难度可能增加。

局限性

  • 本研究为回顾性、单中心、小样本(30例)研究,中位随访仅12.5个月,需要更长期随访评估晚期毒性和肿瘤学结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Treatment of recurrent prostate cancer following prior therapy is challenging due to the risk of toxicities to previously irradiated normal tissues, particularly the rectum. Proton therapy offers a conformal approach that may reduce this risk. Perirectal spacers have been shown to further minimize rectal dose in primary treatment, but the ability to be placed and their value in the retreatment setting have not been thoroughly evaluated to date. The purpose of this study was to evaluate feasibility of rectal spacer placement after prior pelvic radiation or other local treatments for prostate cancer. METHODS AND MATERIALS: We conducted a retrospective review of 30 consecutive patients with biopsy-confirmed, locally recurrent prostate adenocarcinoma treated with salvage proton therapy at the New York Proton Center (2020-2024). All patients had prior local therapies including high intensity focused ultrasound (HIFU), brachytherapy (BT), external beam radiation therapy (EBRT) or combination BT and EBRT, and underwent perirectal spacer placement (SpaceOAR or Barrigel). Spacer feasibility, maximum and minimum separation distances, rectal symmetry, rectal Dmax (% of prescription dose), and gastrointestinal toxicities were assessed. Toxicity was graded using Common Terminology Criteria for Adverse Events, version 5.0. RESULTS: Median patient age was 74 years, and the median time from prior therapy was 102 months. Spacer placement was successfully completed in 28 of 30 (93%) patients. Two placements were aborted due to excessive fibrosis. The median maximum and minimum midaxial anterior-posterior separations were 10.8 mm and 3.5 mm, respectively. Median rectal Dmax was 91.55% (range, 44%-102.4%). Seven patients had Dmax >100%, including 3 with prior HIFU. At a median follow-up of 12.5 months, gastrointestinal toxicities were limited to grade 1 diarrhea (n=3) No grade ≥ 2 toxicities or procedural complications were reported. CONCLUSIONS: This is the first reported study evaluating the feasibility of perirectal spacer implantation in men with prior treatment to the pelvis, undergoing salvage radiation with protons. Our report shows perirectal spacer implantation is feasible and safe in patients undergoing salvage proton therapy, including those with prior EBRT or BT. Although technically more challenging in HIFU-treated patients, successful placement was achieved in the majority, with minimal toxicity and favorable dosimetric outcomes, although longer follow-up is needed.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Yacoub I, Mehta K, Gorovets D, et al. Feasibility and Outcomes of Perirectal Spacer Implantation in Previously Treated Prostate Cancer Patients Undergoing Salvage Proton Therapy Radiation. Adv Radiat Oncol. 2026. PMID: 41716957. doi:10.1016/j.adro.2025.101985

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。